The Expressions And Clinical Implications Of Long Intragenic Non-Coding Rna-P21 And Glucose Transporter 1 In Primary Hepatocellular Carcinoma

Objective: To explore the expressions of long intragenic non-coding RNA-p21 (lincRNA-p21) and glucose transporter 1 (Glut-1) in primary hepatocellular carcinoma (HCC) and their clinical values. Methods: Data for a retrospective study was collected from 264 HCC patients; the relative expressions of lincRNA-p21 and Glut-1 mRNA in the HCC and adjacent normal tissues were measured, and a qualitative analysis was made for Glut-1. Results: The relative expression of lincRNA-p21 in the HCC tissues was lower than it was in the adjacent normal tissues, but the positive rate of Glut-1 and the relative expression of Glut-1 miRNA were higher (all P<0.001). With an increase in the size of the HCC tumors, the alpha fetoprotein (AFP) values became higher, the T stages got higher, the distant metastasis and differentiation of the lymph nodes got poorer, the relative expression of Glut-1 mRNA increased, but the relative expression of RNA-p21 decreased (all P<0.05). The median survival time in the Glut-1 negative patients was longer than in the Glut-1 positive patients (29 months, 95% CI: 27.659-30.341 vs 25 months, 95% CI: 24.133-25.867), and they were significantly different (chi(2) =30.950, P<0.001); the relative expression of lincRNA-p21 was lower in the Glut-1 positive patients than in the Glut-1 negative ones, and the differences were significant (P<0.05). The relative expression of lincRNA-p21 was negatively correlated to Glut-1 miRNA (r=-0.256, P=0.017). Conclusion: LincRNA-p21 and Glut-1 play crucial roles in the occurrence and development of HCC. Decreased lincRNA-p21 but elevated Glut-1 suggests a poor prognosis, and they can be used as biomarkers for judging the malignancy and prognosis of HCC.